Delivery Order SPE2DB22D3004-SPE2DB24FRY07

Award Date 9/24/24
Potential Completion Date 9/25/24
Potential Value $28K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $36,916.53 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of the drug Dupixent 300 mg/2 ml pen, with a period of performance through April 2025. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing pharmaceutical products...
The U.S. Defense Logistics Agency (DLA) awarded a $16,824.83 firm-fixed-price delivery order contract (SPE2DB22D3004|SPE2DB24FPN96) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide 4,563,862,706 units of the medication Dupixent 300 mg/2 ml pen. The contract has an ultimate completion date of March 6, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, which...
This is a $7,762.85 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for 4,564,802,377 units of the medication Dupixent 300 mg/2 ml pen, with a completion date of June 5, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running through November 2026. The IDC covers a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of 4,565,295,902 units of the prescription medication Dupixent 300 mg/2 ml pen (2 ml). The contract has a firm fixed price of $20,064.68 and an ultimate completion date of July 31, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the parent company AmerisourceBergen Corporation. The $14,117.12 contract is for the supply of Dupixent 300 mg/2 ml pen medication. This award is part of a larger indefinite delivery contract (IDC) between DLA Troop Support Medical and AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle...
The U.S. Defense Logistics Agency (DLA) awarded a $53,713.84 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply 4,566 units of the prescription drug Dupixent 300 mg/2 ml pens. The contract has an ultimate completion date of October 16, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the government to...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of 4,565,820,356 units of the medication Dupixent 300 mg/2 ml pen. The contract has a firm fixed price of $72,774.35 and a completion date of September 17, 2024. This order is not associated with a set-aside program. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,029,714 units of the pharmaceutical product Dupixent 300 mg/2 mL pen in 2 mL size. The award, valued at $26,354.74, has a period of performance through March 21, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an Indefinite Delivery Contract (IDC) with DLA valued at up to $999,999,999.00...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,943,360 units of the pharmaceutical product Dupixent 300 mg/2 ml pen. The contract has a ceiling value of $40,898.97 and a period of performance through March 13, 2024. This delivery order is issued under Amerisourcebergen Drug Corp's existing indefinite delivery contract with DLA, valued at up to...
The U.S. Defense Logistics Agency (DLA) awarded a $3,475.70 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of Dupixent 300 mg/2 ml pens. The delivery order is part of a larger $999,999,999.00 single-award Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical...
  • SPE2DB22D3004
    Indefinite Delivery Contract
  • SPE2DB22D3004-SPE2DB24FRY07
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $28,351.01 firm-fixed-price delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,565,924,502 units of the drug Dupixent 300 mg/2 mL pen. This order was placed under an existing Indefinite Delivery Contract (IDC) valued up to $999,999,999 between DLA Troop Support Medical and AmerisourceBergen, which provides a broad range of medical commodities to support military treatment facilities and programs worldwide. The contract does not have a set-aside designation and is scheduled for completion by September 25, 2024.

Generated 12/24/24, 9:37 AM